The press release is largely strategic narrative with limited concrete financials. The $1M in AME revenue is a positive signal but small relative to the $19M market cap. Monitor for actual revenue ramp in upcoming financial reports and progress on medical business monetization. The name change and quantum partnerships could attract speculative interest, but the lack of hard guidance keeps the stock in high-risk territory.
Price Chart
Executive Summary
Inspira Technologies issued a shareholder letter outlining a strategic pivot into quantum connectivity and AME, reporting over $1M in recent AME transactions and a joint development agreement with Qarakal Quantum. The company is also pursuing monetization of its medical business. The letter is heavy on forward-looking statements and lacks hard financial data beyond the $1M revenue figure, making the near-term impact uncertain.
Key Financial Metrics
Key Facts
- Generated over $1 million from recent AME transactions, majority already received in cash.
- Signed a joint development agreement with Qarakal Quantum Ltd. for quantum connectivity solutions.
- Shareholders approved name change to QTREX Quantum Ltd.
- Deployed a commercial AME system at a Tier-1 U.S. defense customer.
- Commenced implementation process with one of the 'Magnificent Seven' U.S. technology companies.
- Actively working to sell parts of the medical business, targeting a term sheet by Q3 2026.
- Terminated ATM and SEPA facilities in March 2026.
- Medical business burn rate has been reduced.
- INSPIRA ART100 has been used in over 40 patients clinically.
Financial Impact
Over $1 million in recent AME transactions; no revenue or EPS figures provided for the overall company.
Risk Factors
- No reported revenue or EPS figures for the overall company; all financial claims are forward-looking.
- Quantum connectivity strategy is pre-revenue and highly speculative.
- Medical business monetization may not materialize as planned.
- Historical win rate on this ticker is low (20% at T+20), suggesting limited predictability.
- High cash burn and reliance on non-dilutive capital from medical sale.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3291784 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 29, 2026 18w ago | Press Release | $3.07 $1.61 | ▼ −47.56% | ▼ −45.76% | — |
May 18, 2026 19w ago | Press Release | $0.3723 $1.29 | ▲ +245.15% | ▲ +243.57% | — |
May 11, 2026 20w ago | Press Release | $0.4070 $1.60 | ▲ +293.12% | ▲ +293.42% | — |
May 1, 2026 22w ago | Press Release | $0.4680 $3.07 | ▲ +555.98% | ▲ +550.70% | — |
Apr 16, 2026 24w ago | Press Release | $0.4950 $0.4050 | ▼ −18.18% | ▼ −24.00% | — |
Apr 14, 2026 24w ago | Press Release | $0.4750 $0.4070 | ▼ −14.32% | ▼ −20.61% | — |
Apr 13, 2026 24w ago | Press Release | $0.5080 $0.4070 | ▼ −19.88% | ▼ −27.61% | — |
Apr 6, 2026 25w ago | Press Release | $0.4110 $0.4780 | ▲ +16.30% | ▲ +7.32% | — |
Apr 6, 2026 25w ago | Press Release | $0.4110 $0.4780 | ▲ +16.30% | ▲ +7.32% | — |
Mar 31, 2026 26w ago | Press Release | $0.4470 $0.4787 | ▲ +7.09% | ▼ −2.33% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access